ERBB2 and neoplasm: T-DXd is an antibody-drug conjugate (ADC) composed of trastuzumab, topoisomerase I inhibitor, and cleavable peptide linker (72).This design enables the precise delivery of its cytotoxic payload into HER2-positive tumor cells, minimizing damage to normal cells (73).